US2023048872A1PendingUtilityA1
Compositions and methods for diagnosing or treating neutrophil-mediated inflammatory disease
Est. expiryJun 28, 2033(~6.9 yrs left)· nominal 20-yr term from priority
A61K 31/05G01N 2800/22A61K 9/5169A61K 31/573G01N 33/5005A61K 9/0019A61K 9/1658
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.
Claims
exact text as granted — not AI-modified1 . A composition comprising nanoparticles, the nanoparticles comprising denatured, cross-linked albumin and an agent selected from a therapeutic agent and a detectable moiety, the nanoparticles being capable of selectively binding to and being internalized by activated neutrophils.
Join the waitlist — get patent alerts
Track US2023048872A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.